July 1, 2008

Anesiva Still at a Great Value

Zacks is out today with an article on Anesiva, a small bio-pharmaceutical company. The article calls the stock "relatively unknown to Wall Street. The shares are significantly undervalued, misunderstood, and poised for a big run over the next several quarters."

I found another article on the company that was written in May where they give the stock a $12 price target.

No comments: